Milestone Pharmaceuticals Inc

NASDAQ MIST

Download Data

Milestone Pharmaceuticals Inc Debt to Tangible Net Worth Ratio 3 year CAGR for the quarter ending September 19, 2024

Milestone Pharmaceuticals Inc Debt to Tangible Net Worth Ratio 3 year CAGR is NA for the quarter ending September 19, 2024. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO Mr. Joseph G. Oliveto M.B.A.
IPO Date May 9, 2019
Location Canada
Headquarters 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees 47
Sector Healthcare
Industry Biotechnology
Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Similar companies

DMAC

DiaMedica Therapeutics Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

CMPX

Compass Therapeutics Inc.

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email